RW
ADIL

Rede Wealth’s Adial Pharmaceuticals ADIL Stock Holding History

Rede Wealth’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24
Closed -$41K – 106
2021
Q4 		$41K Hold
24
– – 0.02% 106
2021
Q3 		$65K Hold
24
– – 0.03% 109
2021
Q2 		$39K Hold
24
– – 0.02% 109
2021
Q1 		$36K Buy
+24
New +$36.3K 0.02% 101

Other funds holding ADIL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rede Wealth's ADIL Position: Q1 2022 in Review

Rede Wealth sold out of Adial Pharmaceuticals (ADIL) in Q1 2022, closing a stake of 24 shares — an estimated $41K sold.

Rede Wealth first reported a position in ADIL in Q1 2021 and held it in 4 quarters. The position peaked at $65K in Q3 2021. 22 funds tracked by Wall St. Rank hold ADIL as of Q1 2022.

  • Rede Wealth reported no remaining Adial Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Rede Wealth sold 24 Adial Pharmaceuticals shares in Q1 2022, an estimated $41K.
  • Rede Wealth first reported a position in Adial Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Rede Wealth's Adial Pharmaceuticals position peaked at $65K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2022.

Based on Rede Wealth's 13F filing for Q1 2022, filed 18 Apr 2022.